Intelgenx Technologies (IGX) Given “Buy” Rating at Aegis

Intelgenx Technologies (CVE:IGX)‘s stock had its “buy” rating reaffirmed by equities researchers at Aegis in a report issued on Monday.

Shares of Intelgenx Technologies (CVE IGX) opened at C$1.06 on Monday. The company has a market capitalization of $68.07, a P/E ratio of -35.33 and a beta of -0.04. Intelgenx Technologies has a 12-month low of C$0.78 and a 12-month high of C$1.39.

Intelgenx Technologies (CVE:IGX) last released its quarterly earnings results on Thursday, November 9th. The company reported C($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of C($0.01).

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/01/intelgenx-technologies-igx-given-buy-rating-at-aegis.html.

About Intelgenx Technologies

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer’s disease.

Receive News & Ratings for Intelgenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelgenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply